Your browser doesn't support javascript.
loading
Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New.
Mackenzie, Samuel J; Nicolau, Stefan; Connolly, Anne M; Mendell, Jerry R.
Afiliação
  • Mackenzie SJ; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics and Neurology; The Ohio State University, Columbus, OH. Electronic address: samuel.mackenzie@nationwidechildrens.org.
  • Nicolau S; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH.
  • Connolly AM; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics and Neurology; The Ohio State University, Columbus, OH.
  • Mendell JR; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics and Neurology; The Ohio State University, Columbus, OH.
Semin Pediatr Neurol ; 37: 100877, 2021 04.
Article em En | MEDLINE | ID: mdl-33892842
ABSTRACT
Duchenne muscular dystrophy (DMD) is marked by pathogenic variants in the DMD gene, leading to reduced or absent dystrophin translation, muscle fiber destruction, loss of ambulation, cardiomyopathy, respiratory failure, and eventually death. Disease progression is slowed with use of prednisone or other corticosteroid agents. Gene replacement therapy, which is one of the focus points of this review, has emerged as the most promising potential treatment for DMD, though alternative RNA-based strategies have been employed for patients with specific pathogenic variants. While challenges remain, many of these novel therapeutic approaches hold promise for treating this devastating disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article